MARKET

KRYS

KRYS

Krystal Biotech
NASDAQ
306.29
-10.01
-3.16%
After Hours: 307.00 +0.71 +0.23% 19:44 05/15 EDT
OPEN
312.29
PREV CLOSE
316.30
HIGH
314.05
LOW
305.99
VOLUME
316.53K
TURNOVER
--
52 WEEK HIGH
319.48
52 WEEK LOW
122.80
MARKET CAP
9.03B
P/E (TTM)
40.96
1D
5D
1M
3M
1Y
5Y
1D
U.K.’s MHRA approves Krystal’s Vyjuvek for dystrophic epidermolysis bullosa
TipRanks · 1d ago
MHRA Approves Beremagene Geperpavec For The Treatment Of Dystrophic Epidermolysis Bullosa
Benzinga · 1d ago
UK'S MHRA: MHRA APPROVES BEREMAGENE GEPERPAVEC (VYJUVEK) FOR TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA
Reuters · 1d ago
Analysts Conflicted on These Healthcare Names: RxSight (RXST), Liquidia Technologies (LQDA) and Krystal Biotech (KRYS)
TipRanks · 2d ago
KRYSTAL BIOTECH INC <KRYS.O>: BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $364 FROM $323
Reuters · 2d ago
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
Reuters · 2d ago
There May Be Underlying Issues With The Quality Of Krystal Biotech's (NASDAQ:KRYS) Earnings
Simply Wall St · 3d ago
Weekly Report: what happened at KRYS last week (0504-0508)?
Weekly Report · 5d ago
More
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.

Webull offers Krystal Biotech Inc stock information, including NASDAQ: KRYS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KRYS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KRYS stock methods without spending real money on the virtual paper trading platform.